Targeting Molecular Resistance in Castration-Resistant Prostate Cancer
Targeting Molecular Resistance in Castration-Resistant Prostate Cancer

Author: Legnica Legnica Press

Publisher:

Published: 2016-01-21

Total Pages: 38

ISBN-13: 9781523629046

DOWNLOAD EBOOK

Multiple mechanisms of resistance contribute to the inevitable progression of hormone-sensitive prostate cancer to castration-resistant prostate cancer (CRPC). Currently approved therapies for CRPC include systemic chemotherapy (docetaxel and cabazitaxel) and agents targeting the resistance pathways leading to CRPC, including enzalutamide and abiraterone. While there is significant survival benefit, primary and secondary resistance to these therapies develops rapidly. Up to one-third of patients have primary resistance to enzalutamide and abiraterone; the remaining patients eventually progress on treatment. Understanding the mechanisms of resistance resulting in progression as well as identifying new targetable pathways remains the focus of current prostate cancer research. We review current knowledge of mechanisms of resistance to the currently approved treatments, development of adjunctive therapies, and identification of new pathways being targeted for therapeutic purposes.

Response and Resistance in Castration-Resistant Prostate Cancer
Response and Resistance in Castration-Resistant Prostate Cancer

Author: Hung-Ming Lam

Publisher:

Published: 2020

Total Pages: 0

ISBN-13:

DOWNLOAD EBOOK

This eBook is a collection of articles from a Frontiers Research Topic. Frontiers Research Topics are very popular trademarks of the Frontiers Journals Series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author by contacting the Frontiers Editorial Office: frontiersin.org/about/contact.

Hormone Therapy and Castration Resistance of Prostate Cancer
Hormone Therapy and Castration Resistance of Prostate Cancer

Author: Yoichi Arai

Publisher: Springer

Published: 2018-05-11

Total Pages: 420

ISBN-13: 981107013X

DOWNLOAD EBOOK

This comprehensive reference expounds the current state of hormone therapy and castration resistance of prostate cancer (PCa). Previously, the incidence of PCa in Asian countries was relatively low, but it has been increasing dramatically in recent years. Although most of the new cases are diagnosed in early stages, a significant proportion of patients receive hormone therapy for metastatic disease or for relapse after local treatment. Thus the situation has gradually changed toward earlier and longer use of hormone therapy. The malignancy finally forms castration-resistant prostate cancer (CRPC) despite the lack of testicular androgen. With advances in understanding of the molecular basis of hormone dependence and CRPC, many new androgen receptor-targeted agents have emerged. During the last decade, much evidence on hormone therapy has been accumulated in Japan. Interestingly, some of these findings are different from those reported from Western countries, suggesting ethnic variation in the outcome of hormone therapy. In the chapters of this book, expert authors provide exhaustive interpretations of the evidence recently reported from Japan and provide important Asian perspectives on hormone therapy for PCa. This work benefits not only Asian urologists but also their Western counterparts and all physicians and medical personnel who are involved in the treatment of PCa.

Response and Resistance in Castration-Resistant Prostate Cancer
Response and Resistance in Castration-Resistant Prostate Cancer

Author: Hung-Ming Lam

Publisher: Frontiers Media SA

Published: 2020-12-24

Total Pages: 99

ISBN-13: 2889662780

DOWNLOAD EBOOK

This eBook is a collection of articles from a Frontiers Research Topic. Frontiers Research Topics are very popular trademarks of the Frontiers Journals Series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author by contacting the Frontiers Editorial Office: frontiersin.org/about/contact.

Therapy Resistance in Prostate Cancer
Therapy Resistance in Prostate Cancer

Author: Hisham Bahmad

Publisher: Elsevier

Published: 2023-10-24

Total Pages: 342

ISBN-13: 0443160333

DOWNLOAD EBOOK

Prostate cancer (PCa) is among the most diagnosed cancers in men worldwide as well as one of the most common causes of cancer-related deaths. Despite the advances in treatment, the disease remains associated with poor survival and resistance to cytotoxic and targeted therapies. Therapy Resistance in Prostate Cancer: Mechanisms and Insights highlights the main mechanisms that are responsible for therapy resistance in PCa allowing researchers and clinicians to have a synopsis of current options and new therapies that can be proposed to overcome this resistance. Understanding the mechanisms responsible for chemotherapy resistance helps researchers all over the world to delve deeper into the pathways behind this resistance and potentially discover new therapeutic targets for PCa. Tackles the topic of resistance from a broader perspective, including, but not limited to, the role of the extracellular matrix and cancer stem cells in therapy resistance Creates understanding on how to develop novel therapies that specifically target CSCs to eliminate the regenerating capacity of the tumor and overcome therapy resistance Helps in identifying novel molecular biomarkers and potential therapeutic targets pertaining to the tumor microenvironment to overcome therapy resistance Provides a general view of the main pathways involved in PCa progression that will aid in understanding the mechanisms responsible for chemotherapy resistance

Management of Castration Resistant Prostate Cancer
Management of Castration Resistant Prostate Cancer

Author: Fred Saad

Publisher: Springer

Published: 2014-08-20

Total Pages: 336

ISBN-13: 1493911767

DOWNLOAD EBOOK

This volume provides new data about the molecular biology of CRPC and a review of the definition, staging and prognostic factors that define CRPC. The book features an in depth review of proven therapeutic options, including bone targeted therapies, immunotherapy, chemotherapy and hormonal based therapies. Combination therapy as well as novel targeted approaches presently under investigations are also reviewed. The text provides up to date guidelines and algorithms for the management of CRPC based on international guidelines presently available as well as evidence based medicine. As a concise yet comprehensive summary of the current status of the field, Management of Castration Resistant Prostate Cancer serves as a very useful resource for physicians and researchers dealing with this challenging malignancy.

Molecular Targeting of Prostate Cancer During Androgen Ablation: Inhibition of CHES1/FOXN3
Molecular Targeting of Prostate Cancer During Androgen Ablation: Inhibition of CHES1/FOXN3

Author:

Publisher:

Published: 2010

Total Pages: 51

ISBN-13:

DOWNLOAD EBOOK

Our operating hypothesis is that checkpoint suppressor 1 (CHES1)/FOXN3 is an androgen withdrawal-induced gene that promotes prostate cancer resistance to apoptosis. The purposes of this research are two-fold. The first is to define the mechanisms of CHES1 gene expression regulation and function, particularly in mediating apoptosis resistance during androgen ablation. Secondly, the tools yielded from our functional studies will be utilized to test the efficacy of CHES1-silencing therapy (CST) in preventing castration-resistant prostate cancer and to develop a mechanism-based noninvasive imaging strategy for monitoring the success of CST. Several significant findings were made. Of major clinical importance, CHES1 expression was elevated substantially during combined androgen blockade and was associated with enhanced PI3K/Akt activation and suppression of pro-apoptotic BNIP3 expression. Conversely, CHES1 down-regulation is potentially necessary for genotoxic stress to trigger apoptosis. To test the hypothesis that CHES1 could be exploited as a therapeutic target, we developed and validated several LNCaP sublines in which we can conditionally silence CHES1 expression, thereby providing us with the necessary models to easily test the value of potential CST. In the coming year, we will test the efficacy of CST to heighten cell killing during androgen ablation and in response to chemotherapy.

Nanostructures for Cancer Therapy
Nanostructures for Cancer Therapy

Author: Alexandru Mihai Grumezescu

Publisher: Elsevier

Published: 2017-04-11

Total Pages: 922

ISBN-13: 0323461506

DOWNLOAD EBOOK

Nanostructures for Cancer Therapy discusses the available preclinical and clinical nanoparticle technology platforms and their impact on cancer therapy, including current trends and developments in the use of nanostructured materials in chemotherapy and chemotherapeutics. In particular, coverage is given to the applications of gold nanoparticles and quantum dots in cancer therapies. In addition to the multifunctional nanomaterials involved in the treatment of cancer, other topics covered include nanocomposites that can target tumoral cells and the release of antitumoral therapeutic agents. The book is an up-to-date overview that covers the inorganic and organic nanostructures involved in the diagnostics and treatment of cancer. Provides an examination of nanoparticle delivery systems for cancer treatment, illustrating how the use of nanotechnology can help provide more effective chemotherapeutic treatments Examines, in detail, the different types of nanomaterials used in cancer therapy, also explaining the effect of each Provides a cogent overview of recent developments in the use of nanostructured materials in chemotherapeutics, allowing readers to quickly familiarize themselves with this area